Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...
Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
PASC, which is otherwise known as long COVID, arises following the recovery from acute infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for ...
In a recent study published in Molecular Psychiatry, researchers review the anti-inflammatory effects of ketamine in the peripheral and central nervous systems. To this end, all relevant articles were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results